波泽利马布:首次获得批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|October 19, 2023
概括
波泽利马布是一种新型抗体疗法,已批准用于治疗CHAPLE疾病,这种罕见的蛋白质丧失肠病. 这种开创性的治疗目标是补充5因子 (C5) 来管理成人和儿童的病情.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 波泽利马布是一种完全人类的IgG4单克隆抗体,旨在抑制补充因子5 (C5).
- 补充通路失调与各种罕见疾病有关.
- CD55缺乏蛋白质损失肠病 (PLE) 或CHAPLE疾病是一种罕见的疾病,治疗选择有限.
研究的目的:
- 总结一下 pozelimab 的发展里程碑.
- 为了突出美国FDA首次批准用于治疗CHAPLE疾病的 pozelimab.
主要方法:
- 对 pozelimab. 的临床发展和监管里程碑的审查.
- 专注于C5抑制的治疗机制.
主要成果:
- 波泽利马布于2023年8月获得美国FDA批准,用于患有CD55缺乏PLE (CHAPLE疾病) 的成人和儿科患者 (≥1岁).
- 这标志着FDA首次批准治疗CHAPLE病的治疗方法.
- 波泽利马布具有对阳性夜间血红蛋白尿 (PNH) 和严重骨髓质疏松症的孤儿药物名称.
结论:
- 波泽利马布在治疗CD55缺乏PLE (CHAPLE疾病) 方面取得了重大进展.
- 该药物的开发突显了针对罕见疾病的补充途径的进展.
- 对于其他补充介导疾病,正在进行进一步的临床开发.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
148
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
148
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy
538
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
538
Preclinical Development: Overview
4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K


